Skip to main content
Premium Trial:

Request an Annual Quote

Reprogen Names President, Closes $5.1 Million Financing Deal


IRVINE, Calif.--Functional genomics firm Reprogen named biophysicist and attorney Jeffrey Miller to the post of president and CEO. In previous positions as senior vice-president, corporate development, at Ostex Interna tion al for one year and at NeoRx for nine years, Miller negotiated strategic alliances with leading pharmaceuticals.

Reprogen also completed $5.1 million in private financing in February. Investors included UBS, Canadian venture fund Genechem, and current investors, Oxford Investors and BIMV, a Belgian venture fund. Reprogen uses functional genomics to identify molecular targets involved in reproductive diseases including endometriosis and ovarian, breast, and prostate cancers.

Filed under

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.